A case study of personalized therapy for osteosarcoma

Lara Davis, Nicolle E. Hofmann, Guangheng Li, Elaine T. Huang, Marc Loriaux, Shay Bracha, Stuart C. Helfand, John E. Mata, Kevin Marley, Atiya Mansoor, Jeffrey Tyner, Jinu Abraham, Bernard Séguin, Charles Keller

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Effective targeted therapies are needed in sarcomas, but the biological heterogeneity of these tumors has presented a challenge to clinical integration of small molecule inhibitors in sarcoma treatment. Here we outline a process to personalize therapy for sarcomas through a case study of a canine with spontaneous osteosarcoma. Procedure: Rapid establishment of a primary tumor cell culture is described, followed by efficient functional characterization of the tumor that identified the Src inhibitor dasatinib as the most effective targeted therapy for this individual dog. Results: Adjuvant dasatinib was administered for a total of 26 weeks following treatment with chemotherapy. Pharmacokinetic studies confirm that a therapeutic serum concentration was achieved at a tolerable dose of 0.75mg/kg/day. The canine patient remains without evidence of recurrent disease 24 months following initial diagnosis. Conclusions: The approach described through this illustrative case study is broadly applicable and might be used for other solid tumors in canines as well as in humans.

Original languageEnglish (US)
Pages (from-to)1313-1319
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Osteosarcoma
Sarcoma
Canidae
Neoplasms
Therapeutics
Primary Cell Culture
Pharmacokinetics
Dogs
Drug Therapy
Serum

Keywords

  • Canine
  • Dasatinib
  • Osteosarcoma
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Davis, L., Hofmann, N. E., Li, G., Huang, E. T., Loriaux, M., Bracha, S., ... Keller, C. (2013). A case study of personalized therapy for osteosarcoma. Pediatric Blood and Cancer, 60(8), 1313-1319. https://doi.org/10.1002/pbc.24512

A case study of personalized therapy for osteosarcoma. / Davis, Lara; Hofmann, Nicolle E.; Li, Guangheng; Huang, Elaine T.; Loriaux, Marc; Bracha, Shay; Helfand, Stuart C.; Mata, John E.; Marley, Kevin; Mansoor, Atiya; Tyner, Jeffrey; Abraham, Jinu; Séguin, Bernard; Keller, Charles.

In: Pediatric Blood and Cancer, Vol. 60, No. 8, 08.2013, p. 1313-1319.

Research output: Contribution to journalArticle

Davis, L, Hofmann, NE, Li, G, Huang, ET, Loriaux, M, Bracha, S, Helfand, SC, Mata, JE, Marley, K, Mansoor, A, Tyner, J, Abraham, J, Séguin, B & Keller, C 2013, 'A case study of personalized therapy for osteosarcoma', Pediatric Blood and Cancer, vol. 60, no. 8, pp. 1313-1319. https://doi.org/10.1002/pbc.24512
Davis, Lara ; Hofmann, Nicolle E. ; Li, Guangheng ; Huang, Elaine T. ; Loriaux, Marc ; Bracha, Shay ; Helfand, Stuart C. ; Mata, John E. ; Marley, Kevin ; Mansoor, Atiya ; Tyner, Jeffrey ; Abraham, Jinu ; Séguin, Bernard ; Keller, Charles. / A case study of personalized therapy for osteosarcoma. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 8. pp. 1313-1319.
@article{52ca4ee6c2f940ce873aca42b16be416,
title = "A case study of personalized therapy for osteosarcoma",
abstract = "Background: Effective targeted therapies are needed in sarcomas, but the biological heterogeneity of these tumors has presented a challenge to clinical integration of small molecule inhibitors in sarcoma treatment. Here we outline a process to personalize therapy for sarcomas through a case study of a canine with spontaneous osteosarcoma. Procedure: Rapid establishment of a primary tumor cell culture is described, followed by efficient functional characterization of the tumor that identified the Src inhibitor dasatinib as the most effective targeted therapy for this individual dog. Results: Adjuvant dasatinib was administered for a total of 26 weeks following treatment with chemotherapy. Pharmacokinetic studies confirm that a therapeutic serum concentration was achieved at a tolerable dose of 0.75mg/kg/day. The canine patient remains without evidence of recurrent disease 24 months following initial diagnosis. Conclusions: The approach described through this illustrative case study is broadly applicable and might be used for other solid tumors in canines as well as in humans.",
keywords = "Canine, Dasatinib, Osteosarcoma, Tyrosine kinase inhibitor",
author = "Lara Davis and Hofmann, {Nicolle E.} and Guangheng Li and Huang, {Elaine T.} and Marc Loriaux and Shay Bracha and Helfand, {Stuart C.} and Mata, {John E.} and Kevin Marley and Atiya Mansoor and Jeffrey Tyner and Jinu Abraham and Bernard S{\'e}guin and Charles Keller",
year = "2013",
month = "8",
doi = "10.1002/pbc.24512",
language = "English (US)",
volume = "60",
pages = "1313--1319",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - A case study of personalized therapy for osteosarcoma

AU - Davis, Lara

AU - Hofmann, Nicolle E.

AU - Li, Guangheng

AU - Huang, Elaine T.

AU - Loriaux, Marc

AU - Bracha, Shay

AU - Helfand, Stuart C.

AU - Mata, John E.

AU - Marley, Kevin

AU - Mansoor, Atiya

AU - Tyner, Jeffrey

AU - Abraham, Jinu

AU - Séguin, Bernard

AU - Keller, Charles

PY - 2013/8

Y1 - 2013/8

N2 - Background: Effective targeted therapies are needed in sarcomas, but the biological heterogeneity of these tumors has presented a challenge to clinical integration of small molecule inhibitors in sarcoma treatment. Here we outline a process to personalize therapy for sarcomas through a case study of a canine with spontaneous osteosarcoma. Procedure: Rapid establishment of a primary tumor cell culture is described, followed by efficient functional characterization of the tumor that identified the Src inhibitor dasatinib as the most effective targeted therapy for this individual dog. Results: Adjuvant dasatinib was administered for a total of 26 weeks following treatment with chemotherapy. Pharmacokinetic studies confirm that a therapeutic serum concentration was achieved at a tolerable dose of 0.75mg/kg/day. The canine patient remains without evidence of recurrent disease 24 months following initial diagnosis. Conclusions: The approach described through this illustrative case study is broadly applicable and might be used for other solid tumors in canines as well as in humans.

AB - Background: Effective targeted therapies are needed in sarcomas, but the biological heterogeneity of these tumors has presented a challenge to clinical integration of small molecule inhibitors in sarcoma treatment. Here we outline a process to personalize therapy for sarcomas through a case study of a canine with spontaneous osteosarcoma. Procedure: Rapid establishment of a primary tumor cell culture is described, followed by efficient functional characterization of the tumor that identified the Src inhibitor dasatinib as the most effective targeted therapy for this individual dog. Results: Adjuvant dasatinib was administered for a total of 26 weeks following treatment with chemotherapy. Pharmacokinetic studies confirm that a therapeutic serum concentration was achieved at a tolerable dose of 0.75mg/kg/day. The canine patient remains without evidence of recurrent disease 24 months following initial diagnosis. Conclusions: The approach described through this illustrative case study is broadly applicable and might be used for other solid tumors in canines as well as in humans.

KW - Canine

KW - Dasatinib

KW - Osteosarcoma

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84875798679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875798679&partnerID=8YFLogxK

U2 - 10.1002/pbc.24512

DO - 10.1002/pbc.24512

M3 - Article

C2 - 23526721

AN - SCOPUS:84875798679

VL - 60

SP - 1313

EP - 1319

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 8

ER -